3-(1H-咪唑-4-基)吡啶 | 51746-85-1

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-(1H-咪唑-4-基)吡啶
• 中文别名: 3-(1H-咪唑)吡啶
• 英文名称: 4(5)-(3-pyridyl)imidazole
• 英文别名: 3-(1H-Imidazol-4-yl)pyridine；3-(1H-imidazol-5-yl)pyridine
• CAS: 51746-85-1
• 化学式: C₈H₇N₃
• mdl: MFCD01691712
• 分子量: 145.164
• InChiKey: YFOKBFRTGLSZLU-UHFFFAOYSA-N

物化性质

• 熔点：
  117-118°C
• 沸点：
  422.4±20.0 °C(Predicted)
• 密度：
  1.214±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于乙醇、甲醇、水

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933990090

SDS

Name:	3-(1H-Imidazol-4-yl)Pyridine Material Safety Data Sheet
Synonym:	4-(3-Pyridyl)Imidazole
CAS:	51746-85-1

Section 1 - Chemical Product MSDS Name:3-(1H-Imidazol-4-yl)Pyridine Material Safety Data Sheet
Synonym:4-(3-Pyridyl)Imidazole

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
51746-85-1	3-(1H-Imidazol-4-yl)Pyridine	ca. 100	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Vapors may be heavier than air. They can spread along the ground and collect in low or confined areas. Runoff from fire control or dilution water may cause pollution.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide. Use agent most appropriate to extinguish fire.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Avoid runoff into storm sewers and ditches which lead to waterways. Clean up spills immediately, observing precautions in the Protective Equipment section. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed.
Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 51746-85-1: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H7N3
Molecular Weight: 145.16

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not currently available.
Conditions to Avoid:
None reported.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 51746-85-1: UT4396500 LD50/LC50:
Not available.
Carcinogenicity:
3-(1H-Imidazol-4-yl)Pyridine - Not listed by ACGIH, IARC, or NTP.
Other:
See actual entry in RTECS for complete information.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
IMO
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
RID/ADR
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing group:

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 51746-85-1: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 51746-85-1 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 51746-85-1 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-(1H-咪唑-4-基)吡啶 在 sodium hydride 、 一水合肼 作用下， 以 乙醇 、 水 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 生成 泰利霉素
  参考文献：
  名称：

  Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens

  摘要：

  In the search for new ketolides with improved activities against erythromycin-resistant S. pneumoniae and H. influenzae we synthesized a new 11,12 carbamate ketolide substituted by an imidazo-pyridyl side chain: HMR 3647. This compound demonstrated a potent activity against erythromycin susceptible and resistant pathogens, including penicillin G/erythromycin A-resistant S. pneumoniae and H. influenzae. In vivo, HMR 3647 displayed good pharmacokinetic parameters (Cmax = 2.9 mu g/ml, bioavailability = 49%, AUC(0-8) = 17.2 mu g.h/l, t(1/2) = 1h) and was shown to have a high therapeutic efficacy in mice infected by various respiratory pathogens, including multi-resistant S. pneumoniae and Gram negative bacteria such as H. influenzae. HMR 3647 appears to be a very promising agent for the treatment of respiratory infections and is currently in clinical trials. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(99)00534-x
• 作为产物：
  描述：

  pyridine-3-ylglyoxal 在 聚合甲醛 、 氨 作用下， 以 水 、 二甲基亚砜 为溶剂， 生成 3-(1H-咪唑-4-基)吡啶
  参考文献：
  名称：

  Production methods of imidazole compound and salt thereof and intermediates therefor

  摘要：

  一种生产方法，包括将式（6）的卤素化合物或其盐在二甲基亚砜中转化为式（2）的甘醛化合物或其盐的步骤，以及将在前一步骤中获得的式（2）的甘醛化合物或其盐与氨和式（3）的醛化合物或其盐反应的步骤，可以方便地生产式（1）的咪唑化合物或其盐。该咪唑化合物是一种作为药物和农业化学品有用的化合物的合成中间体。该生产方法适用于工业规模生产。其中每个符号如规范中所定义。

  公开号：

  US06649768B1

文献信息

• [EN] OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS<br/>[FR] DERIVES D'OXAZOLIDINONE UTILISES COMME AGENTS ANTIMICROBIENS
  申请人：RANBAXY LAB LTD

  公开号：WO2006038100A1

  公开（公告）日：2006-04-13

  The present invention relates to certain substituted phenyl oxazolidinones and to processes for the synthesis of the same. This invention also relates to pharmaceutical compositions containing the compounds of the present invention as antimicrobials. The compounds are useful antimicrobial agents, effective against a number of human and veterinary pathogens, including gram-positive aerobic bacteria, for example, multiple-resistant staphylococci, streptococci and enterococci as well as anaerobic organisms, for example, Bacterioides spp. and Clostridia spp. species, and acid fast organisms, for example, Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium spp.

  本发明涉及某些取代苯基噁唑烷酮以及其合成方法。本发明还涉及含有本发明化合物作为抗微生物药物的药物组合物。这些化合物是有用的抗微生物剂，对多种人类和兽医病原体有效，包括革兰氏阳性厌氧细菌，例如多重耐药葡萄球菌、链球菌和肠球菌，以及厌氧生物，例如Bacterioides属和Clostridia属物种，以及耐酸生物，例如结核分枝杆菌、埃维分枝杆菌和分枝杆菌属。
• PHARMACEUTICAL COMPOUNDS
  申请人：Kiss Laszlo Erno

  公开号：US20120065191A1

  公开（公告）日：2012-03-15

  The invention relates to compounds and compositions for inhibiting the enzyme fatty acid amide hydrolase (FAAH), the use of the compounds in therapy and, in particular, for treating or preventing conditions whose development or symptoms are linked to substrates of the FAAH enzyme, and methods of treatment or prevention using the compounds and compositions.

  这项发明涉及抑制脂肪酰胺水解酶（FAAH）的化合物和组合物，以及在治疗中使用这些化合物，特别是用于治疗或预防与FAAH酶底物相关的疾病的发展或症状的条件，以及使用这些化合物和组合物进行治疗或预防的方法。
• THERAPEUTIC COMPOUNDS AND USES THEREOF
  申请人：Genentech, Inc.

  公开号：US20150065522A1

  公开（公告）日：2015-03-05

  The present invention relates to compounds formula (I): and to salts thereof, wherein R 1 -R 4 and A have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of histone demethylases, such as KDM5. Also included are pharmaceutically acceptable compositions comprising the compounds of the present invention and methods of using said compositions in the treatment of various disorders.

  本发明涉及化合物的化学式（I）及其盐，其中R1-R4和A具有规范中定义的任何值，以及这些化合物的组合物和用途。这些化合物可用作组蛋白去甲基化酶的抑制剂，如KDM5。还包括包含本发明化合物的药用可接受组合物，以及使用这些组合物治疗各种疾病的方法。
• Macrolides with antibacterial activity
  申请人：——

  公开号：US20030199459A1

  公开（公告）日：2003-10-23

  The invention provides new macrolides antibiotics of formula (I) with improved biological properties and improved stability formula (I): wherein R 1 is hydrogen, cyano, —S(L) m R 2 , —S(O)(L) m R 2 , or —S(O) 2 (L) m R 2 ; L represents —(CH 2 ) n — or —(CH 2 ) n Z(CH 2 ) n′ —-; m is 0 or 1; n is 1, 2, 3, or 4; n′ is 0, 1, 2, 3, or 4; Z is O, S or NH; R2 is hydrogen, alkyl, heterocyclyl or aryl; which heterocyclyl and the aryl groups may be further substituted; * indicates a chiral center which is in the (R) or (S) form and pharmaceutically acceptable acid addition salts or in vivo cleavable esters thereof. 1

  该发明提供了具有改进生物性能和改进稳定性的新大环内酯类抗生素的公式(I)：其中R1为氢、氰基、—S(L)mR2、—S(O)(L)mR2或—S(O)2(L)mR2；L代表—(CH2)n—或—(CH2)nZ(CH2)n′—；m为0或1；n为1、2、3或4；n′为0、1、2、3或4；Z为O、S或NH；R2为氢、烷基、杂环烷基或芳基；其中杂环烷基和芳基基团可能进一步取代；*表示手性中心，为(R)或(S)形式，以及其药学上可接受的酸盐或体内可水解酯。
• Process for the synthesis of imidazoles
  申请人：Dolby J. Lloyd

  公开号：US20050101785A1

  公开（公告）日：2005-05-12

  The present invention provides a process for the preparation of imidazoles by reacting a cyano compound with a silylalkylisocyanide compound. Such imidazoles are useful pharmacologically-active compounds and/or intermediates for the preparation of pharmacologically-active compounds.

  本发明提供了一种通过将氰基化合物与硅烷基异氰化合物反应制备咪唑的方法。这些咪唑是有用的药理活性化合物和/或用于制备药理活性化合物的中间体。